Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
LetterLETTER

Update on a Patient with Superficial Siderosis on Deferiprone

M. Levy and R.H. Llinas
American Journal of Neuroradiology June 2012, 33 (6) E99-E100; DOI: https://doi.org/10.3174/ajnr.A3186
M. Levy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.H. Llinas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Superficial siderosis (SS) is a neurodegenerative condition caused by hemosiderin deposition on the surface of the brain, cranial nerves, and spinal cord. SS is an exceptionally rare condition characterized by a triad of hearing loss, ataxia, and myelopathy. The most common etiologies that lead to SS are trauma, previous surgical procedures, dural tears, and tumors of the central nervous system.1 In our letter published on-line November 4, 2010, in the American Journal of Neuroradiology, we demonstrated the efficacy of deferiprone (Ferriprox), a lipid-soluble iron chelator, for reducing hemosiderin deposition through MR imaging of a single patient on deferiprone for 1.5 years.2 On the basis of this case report, we conducted a pilot trial of 10 patients with SS by using 30 mg/kg/day of deferiprone and found that 4 showed MR imaging changes in as little as 3 months.3 As the only treatment to demonstrate any efficacy, deferiprone is emerging as the standard of care for the treatment of SS. With approval of deferiprone by the US Food and Drug Administration in October 2011, we launched an observational trial of deferiprone in superficial siderosis to characterize the potential clinical benefit of hemosiderin chelation (www.clinicaltrials.gov, identifier NCT01284127).

The single subject with SS in the initial case report remained on deferiprone during this time for a total of 3 years 2 months. Clinically, this patient's hearing loss and ataxia, which started 1 year before taking deferiprone, have resolved. He currently has no symptoms. A third MR imaging revealed marked reduction in hemosiderin deposition compared with the original scan and the first follow-up (Fig 1).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Axial T2* brain MR imaging performed before deferiprone therapy (TR/TE, 800/26 ms; A and D) compared with similarly positioned axial T2* MR imaging after 1.5 years of deferiprone therapy (TR/TE, 560/26 ms; B and E) and 3.2 years of deferiprone therapy (TR/TE, 800/26 ms; C and F). Arrows in A and B show hemosiderin hypointensities along the pial surface of the temporal lobe that are now nearly absent in C. In the midbrain, arrows in D and E show hypointensities around the ventral surface of the brain stem that are now much reduced in F (arrowheads).

Deferiprone is unique among iron chelators in that it is lipid-soluble and can penetrate the blood-brain barrier to target hemosiderin in the central nervous system.4 Because it is currently FDA-approved for thalassemia, we are successfully using this drug off-label for the treatment of superficial siderosis at a dose of 1000 mg twice daily, but only 5 days per week to prevent total body iron depletion. We monitor blood counts for agranulocytosis weekly and monthly for liver toxicity and zinc deficiency. Twice yearly MRI confirms the effective chelation of hemosiderin by deferiprone. In our experience, with this patient and others, the clinical response can take many months to years to manifest, depending on the volume and extent of hemosiderin deposition at presentation. Although SS affects fewer than 200 individuals worldwide, we are hopeful that these patients may improve with deferiprone chelation therapy.

References

  1. 1.↵
    1. Levy M,
    2. Turtzo C,
    3. Llinas RH
    . Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol 2007;3:54–58
    CrossRefPubMed
  2. 2.↵
    1. Levy M,
    2. Llinas RH
    . Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. AJNR Am J Neuroradiol 2011;32:E1–2
    Abstract/FREE Full Text
  3. 3.↵
    1. Levy M,
    2. Llinas RH
    . Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke 2012;43:120–24
    Abstract/FREE Full Text
  4. 4.↵
    1. Fredenburg AM,
    2. Sethi RK,
    3. Allen DD,
    4. et al
    . The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996;108:191–99
    CrossRefPubMed
  • © 2012 by American Journal of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 33 (6)
American Journal of Neuroradiology
Vol. 33, Issue 6
1 Jun 2012
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Update on a Patient with Superficial Siderosis on Deferiprone
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Update on a Patient with Superficial Siderosis on Deferiprone
M. Levy, R.H. Llinas
American Journal of Neuroradiology Jun 2012, 33 (6) E99-E100; DOI: 10.3174/ajnr.A3186

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Update on a Patient with Superficial Siderosis on Deferiprone
M. Levy, R.H. Llinas
American Journal of Neuroradiology Jun 2012, 33 (6) E99-E100; DOI: 10.3174/ajnr.A3186
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Pattern Recognition in Mitochondrial Leukodystrophies is Hampered by the Peculiarities of Mitochondrial Genetics
  • Callosal Angle Narrowing in Research Data Bases of the Cognitively Impaired
  • Reply:
Show more Letters

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2021 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2022 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire